Denis Glotz

Denis Glotz

Auto-generated profile, based on publicly available information

Denis Glotz

Department of Nephrology and Transplantation, Hôpital Saint-Louis, Paris, France

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 1999 in Kidney International
Verified
Journal Article
Open access
LRLorraine C. Racusen
Lorraine C. Racusen
KSKim Solez
Kim Solez
RCRobert B. Colvin
Robert B. Colvin
SBStephen M. Bonsib
Stephen M. Bonsib
MCMaria C. Castro
Maria C. Castro
YYYutaka Yamaguchi
Yutaka Yamaguchi
Standardization of renal allograft biopsy interpretation is necessary to guide therapy and to establish an objective end point for clinical trials. This manuscript describes a classification, Banff 97, developed by investigators using the Banff Schema and the Collaborative Clinical Trials in Transplantation (CCTT) modification for diagnosis of renal allograft pathology. Banff 97 grew from an international consensus discussion begun at Banff and continued via the Internet. This schema developed from (a) analysis of data using the Banff classification, (b) publication of and experience with the CCTT modification, (c) international conferences, and (d) data from recent studies on impact of vasculitis on transplant outcome. Semiquantitative lesion scoring continues to focus on tubulitis and arteritis but includes a minimum threshold for interstitial inflammation. Banff 97 defines "types" of acute/active rejection. Type I is tubulointerstitial rejection without arteritis. Type II is vascular rejection with intimal arteritis, and type III is severe rejection with transmural arterial changes. Biopsies with only mild inflammation are graded as "borderline/suspicious for rejection." Chronic/sclerosing allograft changes are graded based on severity of tubular atrophy and interstitial fibrosis. Antibody-mediated rejection, hyperacute or accelerated acute in presentation, is also categorized, as are other significant allograft findings. The Banff 97 working classification refines earlier schemas and represents input from two classifications most widely used in clinical rejection trials and in clinical practice worldwide. Major changes include the following: rejection with vasculitis is separated from tubulointerstitial rejection; severe rejection requires transmural changes in arteries; "borderline" rejection can only be interpreted in a clinical context; antibody-mediated rejection is further defined, and lesion scoring focuses on most severely involved structures. Criteria for specimen adequacy have also been modified. Banff 97 represents a significant refinement of allograft assessment, developed via international consensus discussions.

19 February 2008 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
KSK. Solez
K. Solez
RCR. B. Colvin
R. B. Colvin
LRL. C. Racusen
L. C. Racusen
MHM. Haas
M. Haas
BSB. Sis
B. Sis
RSR. N. Smith
R. N. Smith
The 9th Banff Conference on Allograft Pathology was held in La Coruna, Spain on June 23–29, 2007. A total of 235 pathologists, clinicians and scientists met to address unsolved issues in transplantation and adapt the Banff schema for renal allograft rejection in response to emerging data and technologies. The outcome of the consensus discussions on renal pathology is provided in this article. Major updates from the 2007 Banff Conference were: inclusion of peritubular capillaritis grading, C4d scoring, interpretation of C4d deposition without morphological evidence of active rejection, application of the Banff criteria to zero-time and protocol biopsies and introduction of a new scoring for total interstitial inflammation (ti-score). In addition, emerging research data led to the establishment of collaborative working groups addressing issues like isolated ‘v’ lesion and incorporation of omics-technologies, paving the way for future combination of graft biopsy and molecular parameters within the Banff process.

1 February 2014 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MHMark Haas
Mark Haas
BSB. Sis
B. Sis
LRL. C. Racusen
L. C. Racusen
KSK. Solez
K. Solez
DGD. Glotz
D. Glotz
MMM. Mengel
M. Mengel
The 12th Banff Conference on Allograft Pathology was held in Comandatuba, Brazil, from August 19-23, 2013, and was preceded by a 2-day Latin American Symposium on Transplant Immunobiology and Immunopathology. The meeting was highlighted by the presentation of the findings of several working groups formed at the 2009 and 2011 Banff meetings to: (1) establish consensus criteria for diagnosing antibody-mediated rejection (ABMR) in the presence and absence of detectable C4d deposition; (2) develop consensus definitions and thresholds for glomerulitis (g score) and chronic glomerulopathy (cg score), associated with improved inter-observer agreement and correlation with clinical, molecular and serological data; (3) determine whether isolated lesions of intimal arteritis ("isolated v") represent acute rejection similar to intimal arteritis in the presence of tubulointerstitial inflammation; (4) compare different methodologies for evaluating interstitial fibrosis and for performing/evaluating implantation biopsies of renal allografts with regard to reproducibility and prediction of subsequent graft function; and (5) define clinically and prognostically significant morphologic criteria for subclassifying polyoma virus nephropathy. The key outcome of the 2013 conference is defining criteria for diagnosis of C4d-negative ABMR and respective modification of the Banff classification. In addition, three new Banff Working Groups were initiated.

15 December 2017 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MHMark Haas
Mark Haas
ALA. Loupy
A. Loupy
CLC. Lefaucheur
C. Lefaucheur
CRC. Roufosse
C. Roufosse
DGD. Glotz
D. Glotz
MMM. Mengel
M. Mengel
The kidney sessions of the 2017 Banff Conference focused on 2 areas: clinical implications of inflammation in areas of interstitial fibrosis and tubular atrophy (i-IFTA) and its relationship to T cell–mediated rejection (TCMR), and the continued evolution of molecular diagnostics, particularly in the diagnosis of antibody-mediated rejection (ABMR). In confirmation of previous studies, it was independently demonstrated by 2 groups that i-IFTA is associated with reduced graft survival. Furthermore, these groups presented that i-IFTA, particularly when involving >25% of sclerotic cortex in association with tubulitis, is often a sequela of acute TCMR in association with underimmunosuppression. The classification was thus revised to include moderate i-IFTA plus moderate or severe tubulitis as diagnostic of chronic active TCMR. Other studies demonstrated that certain molecular classifiers improve diagnosis of ABMR beyond what is possible with histology, C4d, and detection of donor-specific antibodies (DSAs) and that both C4d and validated molecular assays can serve as potential alternatives and/or complements to DSAs in the diagnosis of ABMR. The Banff ABMR criteria are thus updated to include these alternatives. Finally, the present report paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next-generation clinical trials.

1 June 2003 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
LRLorraine C. Racusen
Lorraine C. Racusen
RCRobert B. Colvin
Robert B. Colvin
KSKim Solez
Kim Solez
MMMichael J. Mihatsch
Michael J. Mihatsch
PHPhilip F. Halloran
Philip F. Halloran
KTKiril Trpkov
Kiril Trpkov
Antibody‐mediated rejection (AbAR) is increasingly recognized in the renal allograft population, and successful therapeutic regimens have been developed to prevent and treat AbAR, enabling excellent...

26 September 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ALAlexandre Loupy
Alexandre Loupy
CLCarmen Lefaucheur
Carmen Lefaucheur
DVDewi Vernerey
Dewi Vernerey
CPChristof Prugger
Christof Prugger
JHJean-Paul Duong van Huyen
Jean-Paul Duong van Huyen
XJXavier Jouven
Xavier Jouven
Anti-HLA antibodies hamper successful transplantation, and activation of the complement cascade is involved in antibody-mediated rejection. We investigated whether the complement-binding capacity of anti-HLA antibodies plays a role in kidney-allograft failure.